Related Experiment Videos
Trisomy 10 in acute myeloid leukemia
K Ohyashiki1, A Kodama, H Nakamura
1First Department of Internal Medicine, Tokyo Medical College, Japan.
Cancer Genetics and Cytogenetics
|July 15, 1996
Summary
Trisomy 10, a rare chromosome abnormality, was observed in two acute myeloid leukemia (AML) patients. No distinct clinical features were identified, suggesting trisomy 10 may occur in approximately 0.5% of de novo AML cases.
Area of Science:
- Hematology
- Cytogenetics
- Oncology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous clonal hematopoietic stem cell disorder.
- Chromosomal abnormalities are crucial for AML classification and prognosis.
- Trisomy 10 is an uncommon numerical abnormality in AML.
Observation:
- Two de novo AML cases (AML-M0 and AML-M2) presented with trisomy 10 as the sole cytogenetic abnormality.
- Both patients were positive for the CD7 antigen.
- No distinct clinical or hematological features were identified specific to AML with trisomy 10.
Findings:
- Trisomy 10 was identified as the sole chromosomal aberration in two AML patients.
- The CD7 antigen expression was observed in both cases.
- This suggests trisomy 10 may be a rare recurring numerical abnormality in AML.
Implications:
- The incidence of trisomy 10 in de novo AML may be approximately 0.5%.
- Further research is needed to determine the clinical significance and prognostic value of trisomy 10 in AML.
- Identifying rare chromosomal abnormalities contributes to a comprehensive understanding of AML heterogeneity.